Study of ECC4703 with sulfasalazine and pitavastatin
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This early-phase study tests how a new drug (ECC4703) works in the body when taken with two other common medications (sulfasalazine and pitavastatin). Healthy volunteers are needed to help researchers understand potential drug interactions and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old and in good general health.
- No prescription or over-the-counter drugs for 7 days before and during the study.
- Drink no more than 10 alcoholic drinks per week (and no more than 4 in one day).
- No personal or family history of muscle problems (e.g., from statins) or severe skin reactions.
- No major medical conditions (heart, lung, kidney, liver, etc.) or recent surgery or hospitalization.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks how a new medicine, ECC0509, interacts with common drugs like metformin, midazolam, and caffeine in healthy adults. It helps find safe dosing and possible side effects.
This early-stage study tests a new drug called EQ504 in healthy volunteers to see how safe it is and how the body handles it. Participants receive either the drug or a placebo (inactive substance), and the study helps determine the right dose for future research.
This study tests a new medicine called SNS851 in healthy volunteers to see if it is safe and tolerable. It may help people with high liver fat, though it is not yet known if it works.
This trial tests how taking the study drug ECC4703 with or without food affects its levels in the body, and how well the body absorbs it. It helps find the best way to take the drug.
This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
Hear when a new Dyslipidaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.